<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **OV-B (6 of 8)**<br>External request:<br>Submission from Genentech to consider the new FDA approved indications for bevacizumab in platinum-sensitive ovarian cancer. | Based on data in the noted references, the panel consensus was to include carboplatin/paclitaxel/bevacizumab as a category 2A potentially active recurrence therapy option for platinum-sensitive disease. References:  
| **OV-B (5 of 8)/OV-B (6 of 8)**<br>External request:<br>Submission from Clovis Oncology to consider the addition of rucaparib as a single agent for recurrence therapy for patients with either platinum-sensitive or platinum-resistant epithelial ovarian/Fallopian tube/primary peritoneal cancer associated with a tumor BRCA mutation. | Based on data in the noted reference, the panel consensus was to include rucaparib as a category 2A single agent, recurrence therapy option for epithelial ovarian (including LCOH)/Fallopian tube/primary peritoneal cancer. The following footnote has been included: “For patients with deleterious germline and/or somatic BRCA mutated (as detected by an FDA-approved test or other validated test performed in a CLIA-approved facility) advanced ovarian cancer who have been treated with two or more lines of chemotherapy.”  
- Added as a preferred option for platinum-resistant disease  
- Added as a potentially active agent for platinum-sensitive disease | YES: 15  NO: 2  ABSTAIN: 1  ABSENT: 10 |
|                           | Reference:  